Tonix Pharmaceuticals Holding Corp. (TNXP) stock
TNXPNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/3084% below fair value
$3.01−0.23 (-7.10%)
Close on Nov 13, 2026Market cap $51.62MP/E –Yield –
Tonix Pharmaceuticals gross margin
Gross margin is gross profit as a percentage of revenue.
Tonix Pharmaceuticals's gross margin for the twelve months ending Sep 30, 2026 was 89.3%. For fiscal 2025 it was 49.3%, against 23.1% the year before.
Annual gross margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | 49.3% | +26.3 |
| FY2024 | Dec 31, 2024 | 23.1% | −15.9 |
| FY2023 | Dec 31, 2023 | 39.0% | – |
Quarterly gross margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | 92.7% | +34.3 |
| Q2 FY2026 | Jun 30, 2026 | 94.8% | +158.6 |
| Q1 FY2026 | Mar 31, 2026 | 77.1% | +15.9 |
| Q4 FY2025 | Dec 31, 2025 | 80.4% | +26.2 |
| Q3 FY2025 | Sep 30, 2025 | 58.4% | +13.6 |
| Q2 FY2025 | Jun 30, 2025 | -63.8% | −11.3 |
| Q1 FY2025 | Mar 31, 2025 | 61.2% | +28.1 |
| Q4 FY2024 | Dec 31, 2024 | 54.2% | +16.8 |
| Q3 FY2024 | Sep 30, 2024 | 44.9% | +4.4 |
| Q2 FY2024 | Jun 30, 2024 | -52.5% | – |
| Q1 FY2024 | Mar 31, 2024 | 33.1% | – |
| Q4 FY2023 | Dec 31, 2023 | 37.4% | – |
| Q3 FY2023 | Sep 30, 2023 | 40.5% | – |
See a number that looks wrong?